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 RENAL FIBROSIS: DOMINANT 
PARADIGMS AND APPROACHES 
TO TARGET IDENTIFICATION 
 Th e predominant paradigm used to des-
cribe the evolution of tubulointerstitial 
fi brosis in chronic renal disease presents 
a continuum leading from parenchymal 
damage, to the subsequent accumulation 
of infl ammatory  infi ltrate, and fi nally to 
the deposition of mature collagen fi bers by 
an expanded fi broblast population. Chron-
ic renal functional impairment closely 
para llels the evolution of tubulointerstitial 
fi brosis. Th us, remedial action to stop the 
slide in renal function must have among 
its targets the arrest, and if possible the 
reversal, of the fi brotic process. 
 Coherent with the model set out above, 
basic-science studies place an emphasis on 
elucidating both the origin of the expanded 
population of fi broblasts and the molecu-
lar signals governing both their prolifera-
tion and their role in the synthesis and 
remodeling of the extracellular matrix. 1 
 With these goals in mind, research 
eff orts frequently set a course toward the 
discovery of specific ligand – receptor 
interactions implicated in the fibrotic 
response in order to identify  ‘ druggable ’ 
targets. Th is has led to well-documented 
successes such as interventions along the 
renin – angiotensin system pathway. Th ese 
have proven eff ective in putting the brakes 
on the progression of tubulointerstitial 
fibrosis through both blood pressure-
dependent and -independent (including 
direct antifi brotic) pathways. 2 Some of the 
direct antifi brotic eff ects of manipulation 
of the renin – angiotensin system pathway 
are likely to rely on the modifi cation of 
transforming growth factor-  (TGF-  ) 
bioactivity. Frustratingly, however, despite 
the level to which the elucidation of the 
TGF-  signaling pathway has leveraged 
signifi cant advances in our precise under-
standing of the fi brotic process, for the 
most part it has yet to fully deliver on the 
promise of  ‘ druggable ’ pathways. 3 Th is 
may refl ect myriad responses to TGF-  in 
multiple cell types. 
 THE EVOLVING CONCEPT OF 
BY-PRODUCTS OF TISSUE INJURY 
AS PROFIBROTIC LIGANDS 
 Th e variety of cellular responses to TGF-
  may complicate drug design, but it does 
not directly challenge the preeminence 
of the specifi c ligand – receptor approach 
to rational drug design. However, other 
pheno mena that are currently coming to 
light may well increasingly challenge this 
approach, particularly contemporary ad-
vances in our appreciation of the exis tence 
of diverse and oft en disease-specifi c mol-
ecules generated as by-products of tissue 
injury. 4 Specifi c domains on these intracel-
lularly or extracellularly derived molecules 
can act as damage-associated molecular 
patterns (DAMPs). DAMPs can be recog-
nized as ligands by pattern recognition re-
ceptors. Th e apparent receptor redundan-
cy operative in these types of interactions 
suggests that they might radically defy 
the established norms of ligand – receptor 
complementarity. 
 FIBRINOGEN MEDIATES RENAL 
FIBROBLAST PROLIFERATION:  IN VIVO 
AND  IN VITRO EVIDENCE 
 S ö rensen  et al. 5 (this issue) present evi-
dence for the existence of a complex 
yet intriguingly intuitive example of an 
apparently promiscuous receptor-based 
interaction between the renal fi broblast 
and fi brinogen, through which fi brino-
gen acts as a proliferative signal. 
 Fibrinogen is a large hexameric plasma 
glycoprotein and precursor to the fi brin 
structural scaff old so centrally important to 
hemostasis and eff ective wound healing. 
The variety of mechanisms by which it 
effects a role in wound healing extends 
beyond its participation in provisional clot 
formation and contraction to include a role 
as a reservoir for growth factors, enzymes, 
enzyme inhibitors, and matrix proteins and 
also as a ligand for cell-surface receptors. It 
is in this last context that S ö rensen  et al. 5 
consider fi brinogen. 
 Th e authors set out to compare tubulo-
interstitial inflammation and fibrosis 
at 7 and 14 days aft er unilateral ureteric 
obstruction (UUO) in fibrinogen-null 
adult female C57BL / 6J mice (  −  /  −  ) and 
their heterozygous littermates (  +  /  −  ). 
 Th e authors demonstrate that in spite of 
comparable levels of hydronephrosis and 
resultant inflammatory-cell count in 
fi brinogen   −  /  −   and fi brinogen   +  /  −   mice, 
there is a relative reduction in fi broblast 
number and an attenuated deposition of 
collagen in the tubulointerstitium of 
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fi brinogen-null mice. Furthermore, this 
fibrinogen acts as a renal fibroblast 
mitogen  in vitro , at least in part through 
the engagement of Toll-like receptor 2 
(TLR2), TLR4, and intercellular adhesion 
molecule-1 (ICAM-1). Th is proliferative 
activity is specifi c to fi broblasts and does 
not occur in renal epithelial cell lines of 
either proximal tubular or collecting duct 
origin. Accordingly, the authors conclude 
that fibrinogen is a receptor-mediated 
mitogen for renal fi broblasts and hence a 
potentially important driver of tubu-
lointerstitial fi brosis. 
 Th e fact that fi brinogen can directly act 
as a renal fibroblast mitogen  in vitro 
would suggest that this activity is not 
dependent on thrombin- and factor 
XIIIa-induced formation of mature fi brin. 
Equally well, it does not rule out the pos-
sibility that polymerized fibrin could 
retain this mitogenic property. If the lat-
ter is true, it suggests that mediators of 
fi brinolysis may have potential to directly 
act as antifi brotic agents. Indeed, both 
genetic ablation and pharmacological 
decoy of plasminogen activator inhibitor-
1 (PAI-1) activity in the UUO model elicit 
marked antifi brotic eff ects. 6,7 However, 
paradoxically, these effects appear to 
depend more on the activation of plas-
minogen activator targets other than 
plasminogen itself, such as hepatocyte 
growth factor. 7 
 FIBRINOGEN AND FIBROBLAST 
PROLIFERATION: A SUBTLE PARADIGM 
SHIFT 
 Either way, the mitogenic role described 
for fi brinogen represents a subtle para-
digm shift  in our understanding of the 
role of coagulation factors in renal injury 
and fi brosis progression. 
 It can be described as a ligand – receptor 
interaction unlikely to occur under normal 
circumstances because of the compart-
mentalization of interstitial and vascular 
spaces and the sequestration of fi brinogen 
within the latter. It would logically seem to 
depend on plasma protein extravasation 
and hence should take place only in the 
setting of renal injury. This hypothesis 
works on the assumption that there is no 
intrinsic interstitial source of fi brinogen 
and that the fi brin deposits observed in 
renal injury are plasma derived and hepatic 
in origin. Th is being the case, the receptor-
mediated cell-signaling activity of fi brino-
gen can thus be described as being 
 ‘ DAMP-like. ’ 
 Th e data describing a role for TLR2 and 
TLR4 as putative receptors for the 
mitogenic eff ect of fi brinogen further sup-
port the description of its activity as 
DAMP-like, given that both TLRs have 
been implicated as mediators of signaling 
by a diverse range of both intracellularly 
and extracellularly derived DAMPs (for 
instance, heat-shock proteins, high-mobil-
ity group box-1, versican, long-chain satu-
rated fatty acids). 4 Although the data of 
S ö rensen  et al. 5 implicate both TLR2 and 
TLR4 in fi broblast proliferation in obstruc-
tive nephropathy via a MyD88 / nuclear fac-
tor-  B-dependent pathway, the results 
from models of UUO in TLR4- and TLR2-
null mice are not entirely coherent with 
this picture of events. No overall alteration 
in renal extracellular matrix deposition is 
observed in TLR2-null mice in the UUO 
model, although there is a reduction in 
interstitial fi broblast number that occurs at 
later stages. 8 On the other hand, TLR4-null 
mice do show a reduction in extracellular 
matrix accumulation following UUO, but 
this is described as occurring in the absence 
of a change in interstitial fi broblast number 
and is instead attributed to a titrated antag-
onism of TGF-  signaling occurring sec-
ondary to increases in the levels of Bambi, 
the membrane-bound competitive inhibi-
tor of the TGF-  type 1 receptor. 9 Whether 
redundancy between the TLR2 and TLR4 
receptors or compensatory changes in 
other putative fi brinogen receptors such as 
ICAM-1 infl uence the results obtained in 
receptor-null mice is unclear. 
 Consistent with their role in microbial 
sensing, the TLRs are highly expressed on 
cells of the innate arm of the immune 
response. It is somewhat surprising, then, 
that S ö rensen  et al. 5 do not find any 
quantitative alteration in the post-UUO 
infl ammatory infi ltrate in fi brinogen-null 
mice. Whether a qualitative difference 
in immune activation exists in fi brino gen-
null mice in terms of the phenotypic plas-
ticity of infiltrating cells may warrant 
further study. 
 PERSPECTIVES 
 In closing, it should be emphasized that 
the description of fi brinogen as a fi bro blast 
mitogen has potentially signifi cant reper-
cussions for our understanding of the role of 
the coagulation cascade in progressive renal 
injury. It has been noted that circulating fi -
brinogen levels show an independent posi-
tive correlation with the rate of renal disease 
progression in the elderly. 10 It can be logi-
cally assumed that this association relies in 
large part on the prothrombotic eff ects of fi -
brinogen, with their attendant consequenc-
es for renal microvascular injury. However, 
as discussed herein, the results of S ö rensen 
 et al. 5 raise the possibility that a direct 
DAMP-like, profi brotic eff ect of fi brinogen 
may also play an impor tant role in this asso-
ciation and in the evolution of renal fi brosis 
in a wider sense. Some of the key questions 
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 Figure 1  |  Questions arising from the description of a Toll-like receptor-mediated mitogenic 
role for fibrinogen in renal fibroblasts. MyD88, myeloid differentiation primary response gene; 
NF-  B, nuclear factor-  B; TLR, Toll-like receptor; UUO, unilateral ureteric obstruction . 
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surrounding the central focus of the report 
of S ö rensen  et al. , 5 most particularly those 
posed by the proposed role for TLR signal-
ing, are presented in  Figure 1 . 
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 Short-term effects of vitamin D 
receptor activation on serum 
creatinine, creatinine generation, 
and glomerular filtration 
 Matthew R.  Weir 1 
 Vitamin D receptor activation may have pleiotropic effects in a variety 
of tissues. Experimental studies with vitamin D receptor activation 
demonstrate an ability to delay progression of renal disease. In 
humans, vitamin D receptor activation reduces albuminuria. Yet some 
clinical studies demonstrate that patients receiving vitamin D 
supplementation have an elevation in serum creatinine and a decline 
in estimated glomerular filtration rate. These observations may be 
explainable by an effect of vitamin D receptor activation on creatinine 
metabolism. 
 Kidney International (2011)  80, 1016 – 1017.  doi: 10.1038/ki.2011.265 
 Vitamin D receptor activation has been 
demonstrated to have multiple eff ects in 
a variety of tissues. 1 Th ese pleiotropic 
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effects may limit bone loss, but also 
reduce mortality in patients with kidney 
disease, and possibly attenuate the rate 
of progression of renal disease. The 
explanation for these benefi ts is elusive 
but may involve not only diminished lev-
els of parathyroid hormone but perhaps 
attenuation of hormonal and proinfl am-
matory systems that may promote scar-
ring and fi brosis ( Figure 1 ). Despite the 
observed benefi ts with regard to mortal-
ity in patients with kidney disease, 2 and 
the reduction of albuminuria, 3 which is 
a perceived surrogate of renal protection, 
a lingering concern is the evidence in a 
number of patients of a decline in esti-
mated glomerular fi ltration rate. Might 
the pleiotropic effects of vitamin D 
receptor activation possess both benefi -
cial and detrimental eff ects on kidney 
function? 
 Experimental studies have demon-
strated that inadequate vitamin D 
receptor activation worsens diabetic 
nephropathy through increased fi bronec-
tin production and decreased nephrin 
expression. 4 Moreover, vitamin D recep-
tor activation suppresses high-glucose-
induced activation of the renin – angiotensin 
system and transforming growth factor-
  . 5 In other experimental models of 
nephropathy, vitamin D receptor activa-
tion attenuates renal interstitial fi brosis 
and limits epithelial-to-mesenchymal 
transition. 6 
 In clinical studies, vitamin D receptor 
activation facilitates an antiproteinuric 
response that is incremental to blood 
pressure reduction and renin – angi-
otensin system blockade. 3 Yet the increase 
in serum creatinine observed during 
these studies raises important questions 
about the overall long-term benefi t of 
vitamin D receptor activation for kidney 
function. 
 A number of important clues in the 
clinical literature provide perspective. 
First, the eff ect of vitamin D on serum 
creatinine was reversible aft er the cessa-
tion of therapy. 7 Second, in small studies, 
the reduction in creatinine clearance 
associated with vitamin D therapy was 
not seen in patients who had simultane-
ous measurement of glomerular fi ltration 
rate. 7 Th ird, other older studies, albeit 
small, have suggested that vitamin D 
receptor activation may alter creatinine 
metabolism and / or its handling by the 
kidney. 8 Consequently, the small but 
well-done study by Agarwal  et al. 9 (this 
issue), in which they examined the eff ect 
of vitamin D receptor activation on cre-
atinine metabolism and measured 
glomerular fi ltration rate, and its revers-
ibility, is quite important. 
